CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
Status unconfirmed · Phase 2
Conditions studied: Brain and Central Nervous System Tumors, Recurrent Glioblastoma Multiforme
In brief
RATIONALE: CT-322 may stop the growth of glioblastoma multiforme by blocking blood flow to the tumor. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving CT-322 together with irinotecan may kill more tumor cells. PURPOSE: This phase 2 trial is studying the side effects, tolerability, and efficacy of CT-322 when given alone and in combination with irinotecan to patients with glioblastoma multiforme.
Key facts
- Study ID
- NCT00562419
- Run by
- Adnexus, A Bristol-Myers Squibb R&D Company
- People needed
- 72
- Starts
- 2007-10-01
- Expected to finish
- 2011-12-01
- Last updated by the study team
- 2010-10-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California, San Diego — La Jolla, California, United States
- University of Kentucky — Lexington, Kentucky, United States
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Henry Ford Health System — Detroit, Michigan, United States
- SUNY Upstate Medical University — Syracuse, New York, United States
- Duke University Medical Center — Durham, North Carolina, United States
- Rhode Island Hospital — Providence, Rhode Island, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- University of Virgina — Charlottesville, Virginia, United States
- University of Wisconsin Hospital — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.